This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Aldeyra Therapeutics Faces Class Actions
Business class action lawsuit

Aldeyra Therapeutics Faces Class Actions

Analysis based on 80 articles · First reported Apr 24, 2026 · Last updated May 30, 2026

Sentiment
-70
Attention
6
Articles
80
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The multiple class action lawsuits against Aldeyra Therapeutics, stemming from the United States — Food and Drug Administration's rejection of its drug candidate reproxalap, have led to a significant decline in Aldeyra Therapeutics' stock price. This event highlights the risks associated with pharmaceutical companies relying heavily on a single drug candidate and the potential for investor losses due to alleged misleading statements. The legal actions by firms like Bronstein, Gewirtz & Grossman, LLC, Rosen Law Firm, The Schall Law Firm, and Pomerantz LLP aim to recover damages for affected investors, potentially impacting investor confidence in similar biotech ventures.

pharmaceuticals legal services
Event Summary

Aldeyra Therapeutics is facing multiple class action lawsuits from various investor-rights law firms, including Bronstein, Gewirtz & Grossman, LLC, Rosen Law Firm, The Schall Law Firm, and Pomerantz LLP. These lawsuits allege that Aldeyra Therapeutics made false and misleading statements regarding the clinical trials of its drug candidate, reproxalap, between November 3, 2023, and March 16, 2026. The core of the complaints is that the trial results for reproxalap were inconsistent, rendering any purported positive findings unreliable. This situation came to light after the United States — Food and Drug Administration issued a Complete Response Letter for reproxalap, citing a 'lack of substantial evidence' and 'inconsistency of study results' for the treatment of dry eye disease. Following this news, Aldeyra Therapeutics' stock price plummeted by over 70%. The lawsuits seek to recover damages for investors who suffered losses during the specified Class Period, with a lead plaintiff deadline set for May 29, 2026.

Entities Involved
stock
Aldeyra Therapeutics
Aldeyra Therapeutics is the primary defendant in multiple class action lawsuits filed by various law firms, alleging that the company made false and misleading statements regarding the clinical trials of its drug candidate, reproxalap. The company's stock price fell significantly after the United States — Food and Drug Administration issued a Complete Response Letter for reproxalap.
Importance 100.0 Sentiment -75.0
priv
Rosen Law Firm
Rosen Law Firm is a global investor rights law firm that reminds purchasers of Aldeyra Therapeutics securities about the lead plaintiff deadline in the securities class action it first filed.
Importance 90.0 Sentiment 45.0
priv
Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC is an investor-rights law firm that has filed a class action lawsuit against Aldeyra Therapeutics, seeking to recover damages for investors.
Importance 85.0 Sentiment 40.0
priv
Pomerantz LLP
Pomerantz LLP announces a class action lawsuit against Aldeyra Therapeutics, advising investors to contact them regarding the case.
Importance 75.0 Sentiment 38.0
priv
DJS Law Group
DJS Law Group is one of the law firms reminding investors of the class action lawsuit against Aldeyra Therapeutics and encouraging shareholders to participate.
Importance 70.0 Sentiment 20.0
priv
Faruqi & Faruqi
Faruqi & Faruqi is investigating potential claims against Aldeyra Therapeutics and reminding investors of the deadline to seek the role of lead plaintiff in the federal securities class action.
Importance 70.0 Sentiment 20.0
priv
Kirby McInerney LLP
Kirby McInerney LLP is the law firm representing investors in the securities class action lawsuit against Aldeyra Therapeutics, seeking lead plaintiff appointments and managing the litigation.
Importance 70.0 Sentiment 50.0
priv
The Schall Law Firm
The Schall Law Firm is a national shareholder rights litigation firm that reminds investors of a class action lawsuit against Aldeyra Therapeutics for alleged securities law violations.
Importance 70.0 Sentiment 35.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration issued a Complete Response Letter to Aldeyra Therapeutics, citing a lack of substantial evidence for the efficacy of reproxalap, which triggered the stock price drop and subsequent lawsuits.
Importance 70.0 Sentiment 0.0
oth
Reproxalap
Reproxalap is an investigational drug candidate by Aldeyra Therapeutics for dry eye disease, which failed to receive United States — Food and Drug Administration approval, leading to the company's stock decline and the class action lawsuit.
Importance 60.0 Sentiment -80.0
per
Peretz Bronstein
Peretz Bronstein is a founding partner of Bronstein, Gewirtz & Grossman, LLC, actively involved in the class action lawsuit against Aldeyra Therapeutics.
Importance 60.0 Sentiment 30.0
per
Philip Kim
Philip Kim is an attorney at Rosen Law Firm, providing information and assistance to investors regarding the Aldeyra Therapeutics class action.
Importance 60.0 Sentiment 30.0
per
Lawrence Rosen
Lawrence Rosen, a founding partner of Rosen Law Firm, is mentioned as a key figure in the firm's success in securities class actions, which is handling the lawsuit against Aldeyra Therapeutics.
Importance 60.0 Sentiment 22.0
per
Brian Schall
Brian Schall is associated with The Schall Law Firm and encourages investors to contact the firm regarding the Aldeyra Therapeutics class action lawsuit.
Importance 50.0 Sentiment 25.0
per
Nathan Miller
Nathan Miller is a Client Relations Manager at Bronstein, Gewirtz & Grossman, LLC, assisting with investor inquiries regarding the Aldeyra Therapeutics class action.
Importance 40.0 Sentiment 20.0
+ 6 more entities View on Dashboard
Relationships
Aldeyra Therapeutics related ↔ Rosen Law Firm
Aldeyra Therapeutics related ↔ Bronstein, Gewirtz & Grossman, LLC
Aldeyra Therapeutics related ↔ DJS Law Group
Aldeyra Therapeutics related ↔ Faruqi & Faruqi
Aldeyra Therapeutics related ↔ United States — Food and Drug Administration
Rosen Law Firm competitor ↔ Bronstein, Gewirtz & Grossman, LLC Rosen Law Firm competes directly with Bronstein, Gewirtz & Grossman, LLC in the field of investor rights litigation. The
Rosen Law Firm competitor ↔ Pomerantz LLP Rosen Law Firm competes directly with Pomerantz LLP in the plaintiff-side securities litigation market, often investigat
Rosen Law Firm related ↔ DJS Law Group
Rosen Law Firm competitor ↔ Faruqi & Faruqi Rosen Law Firm competes directly against Faruqi & Faruqi in the securities litigation space, as both firms regularly sol
Rosen Law Firm related ↔ Kirby McInerney LLP
Rosen Law Firm competitor ↔ The Schall Law Firm Rosen Law Firm operates as a direct competitor to The Schall Law Firm, with both practices frequently competing to repre
Rosen Law Firm related ↔ United States — Food and Drug Administration
Bronstein, Gewirtz & Grossman, LLC co-plaintiffs ↔ Pomerantz LLP Bronstein, Gewirtz & Grossman, LLC frequently collaborates with Pomerantz LLP as co-plaintiffs in numerous class action
Bronstein, Gewirtz & Grossman, LLC co-plaintiffs ↔ DJS Law Group Bronstein, Gewirtz & Grossman, LLC frequently acts as a co-plaintiff with DJS Law Group in numerous securities fraud cla
Bronstein, Gewirtz & Grossman, LLC competitor ↔ Faruqi & Faruqi Bronstein, Gewirtz & Grossman, LLC is a securities litigation law firm that directly competes with Faruqi & Faruqi to re
+ 18 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.